Generic placeholder image

Current HIV Research

Author(s): Yadiel Corrales Cruz, Corey Suthumphong, Allen Caobi, Mickensone Andre, Janelle Vicens, Andrea D. Raymond and Marco Ruiz*

DOI: 10.2174/011570162X288575240821201433

DownloadDownload PDF Flyer Cite As
MicroRNA Expression in Exosome Extracellular Vesicles as Targets for Personalized Medicine in Diffuse Large B Cell Lymphoma Patients with HIV Infection

Page: [354 - 360] Pages: 7

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

Extracellular Vesicles (EVs), more specifically exosomes (xEVs), have been associated with Diffuse Large B-cell Lymphoma (DLBCL). These xEVs contain a variety of biomolecules, such as proteins and nucleic acids (e.g., microRNA, LncRNA, and DNA). The expressions of these vesicles in the setting of Human Immunodeficiency Virus (HIV) have been linked to disease progression. Studies have explored the use of EVs in more practical clinical settings. Several studies have found that biomolecules within xEVs can serve to detect disease progression. The biomolecule content within xEVs is useful in prognostication and has even been associated with mechanisms of resistance for some DLBCL treatment modalities. This review article explores the role of xEV biomolecule content in DLBCL progression in the context of HIV infection and its applied use in practical disease management.

Keywords: Biomarkers, HIV, microRNA, exosomes, EVs, DLBCL.

Graphical Abstract

[1]
Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: A review of 1028 cases. Blood 2012; 120(24): 4795-801.
[http://dx.doi.org/10.1182/blood-2012-07-440073] [PMID: 23086753]
[2]
Ofori K, Bhagat G, Rai AJ. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs. Br J Clin Pharmacol 2021; 87(2): 284-94.
[http://dx.doi.org/10.1111/bcp.14611] [PMID: 33080045]
[3]
Sirsath N, Sathyanarayanan V, Setty GBK, Channaviriappa LK, Nagendrappa LK, Dasappa L. Human Immunodeficiency Virus - associated lymphomas: A neglected domain. N Am J Med Sci 2013; 5(7): 432-7.
[http://dx.doi.org/10.4103/1947-2714.115772] [PMID: 24020054]
[4]
Carbone A, Vaccher E, Gloghini A, et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients. Nat Rev Clin Oncol 2014; 11(4): 223-38.
[http://dx.doi.org/10.1038/nrclinonc.2014.31] [PMID: 24614140]
[5]
Magangane P, Sookhayi R, Govender D, Naidoo R. Determining protein biomarkers for DLBCL using FFPE tissues from HIV negative and HIV positive patients. J Mol Histol 2016; 47(6): 565-77.
[http://dx.doi.org/10.1007/s10735-016-9695-y] [PMID: 27696080]
[6]
Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology 2018; 50(1): 74-87.
[http://dx.doi.org/10.1016/j.pathol.2017.09.006] [PMID: 29167021]
[7]
Xue Y, Wang Q, He X. Clear cell variant of diffuse large B-cell lymphoma: A case report and review of the literature. Int J Clin Exp Pathol 2015; 8(6): 7594-9.
[PMID: 26261675]
[8]
Anyanwu SI, Doherty A, Powell MD, et al. Detection of HIV-1 and human proteins in urinary extracellular vesicles from HIV+ patients. Adv Virol 2018; 2018: 1-16.
[http://dx.doi.org/10.1155/2018/7863412] [PMID: 29721020]
[9]
Dias MVS, Costa CS, daSilva LLP. The ambiguous roles of extracellular vesicles in HIV replication and pathogenesis. Front Microbiol 2018; 9: 2411.
[http://dx.doi.org/10.3389/fmicb.2018.02411] [PMID: 30364166]
[10]
Thery C. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current Protocol In Cell Biology. Hoboken, New Jersey: Wiley 2006.
[http://dx.doi.org/10.1002/0471143030.cb0322s30]
[11]
Colombo M, Moita C, van Niel G, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci 2013; 126(Pt 24): jcs.128868.
[http://dx.doi.org/10.1242/jcs.128868] [PMID: 24105262]
[12]
Zhang B, Wu X, Zhang X, et al. Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/β-catenin pathway. Stem Cells Transl Med 2015; 4(5): 513-22.
[http://dx.doi.org/10.5966/sctm.2014-0267] [PMID: 25824139]
[13]
Zhang B, Wang M, Gong A, et al. HucMSC-exosome mediated-wnt4 signaling is required for cutaneous wound healing. Stem Cells 2015; 33(7): 2158-68.
[http://dx.doi.org/10.1002/stem.1771] [PMID: 24964196]
[14]
Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): A platform for glioblastoma biomarker development. PLoS One 2013; 8(10): e78115.
[http://dx.doi.org/10.1371/journal.pone.0078115] [PMID: 24205116]
[15]
van Niel G, Théry C. Extracellular vesicles: Eat glutamine and spit acidic bubbles. EMBO J 2020; 39(16): e105119.
[http://dx.doi.org/10.15252/embj.2020105119] [PMID: 32809264]
[16]
Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: Biogenesis, biologic function and clinical potential. Cell Biosci 2019; 9(1): 19.
[http://dx.doi.org/10.1186/s13578-019-0282-2] [PMID: 30815248]
[17]
Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Curr Opin Cell Biol 2014; 29: 116-25.
[http://dx.doi.org/10.1016/j.ceb.2014.05.004] [PMID: 24959705]
[18]
Feng Y, Zhong M, Zeng S, et al. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019; 11(1): 35-51.
[http://dx.doi.org/10.2217/epi-2018-0123] [PMID: 30211623]
[19]
Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008; 142(5): 732-44.
[http://dx.doi.org/10.1111/j.1365-2141.2008.07237.x] [PMID: 18537969]
[20]
Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141(5): 672-5.
[http://dx.doi.org/10.1111/j.1365-2141.2008.07077.x] [PMID: 18318758]
[21]
Ji M, Rao E, Ramachandrareddy H, et al. The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies. Am J Pathol 2011; 179(4): 1645-56.
[http://dx.doi.org/10.1016/j.ajpath.2011.06.008] [PMID: 21806958]
[22]
Carvalho AS, Baeta H, Henriques AFA, et al. Proteomic landscape of extracellular vesicles for diffuse large B-cell lymphoma subtyping. Int J Mol Sci 2021; 22(20): 11004.
[http://dx.doi.org/10.3390/ijms222011004] [PMID: 34681663]
[23]
Di C, Jiang Y, Li M, Juan X, Xu C. Circulating exosomal microrna signature as a noninvasive biomarker for diagnosis of diffuse large B-cell lymphoma. Blood 2018; 132 (Suppl. 1): 5406-6.
[http://dx.doi.org/10.1182/blood-2018-99-115940]
[24]
van Eijndhoven MAJ, Zijlstra JM, Groenewegen NJ, et al. Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients. JCI Insight 2016; 1(19): e89631.
[http://dx.doi.org/10.1172/jci.insight.89631] [PMID: 27882350]
[25]
Aharon A, Rebibo-Sabbah A, Tzoran I, Levin C. Extracellular vesicles in hematological disorders. Rambam Maimonides Med J 2014; 5(4): e0032.
[http://dx.doi.org/10.5041/RMMJ.10166] [PMID: 25386348]
[26]
Diehl P, Fricke A, Sander L, et al. Microparticles: Major transport vehicles for distinct microRNAs in circulation. Cardiovasc Res 2012; 93(4): 633-44.
[http://dx.doi.org/10.1093/cvr/cvs007] [PMID: 22258631]
[27]
Rutherford SC, Fachel AA, Li S, et al. Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. Blood 2018; 132(7): e13-23.
[http://dx.doi.org/10.1182/blood-2017-12-821843] [PMID: 29967128]
[28]
Bach DH, Hong JY, Park HJ, Lee SK. The role of exosomes and miRNAs in drug-resistance of cancer cells. Int J Cancer 2017; 141(2): 220-30.
[http://dx.doi.org/10.1002/ijc.30669] [PMID: 28240776]
[29]
Troppan K, Wenzl K, Deutsch A, Ling H, Neumeister P, Pichler M. MicroRNAs in diffuse large B-cell lymphoma: Implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2014; 34(2): 557-64.
[PMID: 24510984]
[30]
Yuan WX, Gui YX, Na WN, Chao J, Yang X. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett 2016; 11(1): 423-32.
[http://dx.doi.org/10.3892/ol.2015.3866] [PMID: 26870228]
[31]
Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RCT. MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 ( TNFAIP3, A20 ). Proc Natl Acad Sci USA 2012; 109(20): 7865-70.
[http://dx.doi.org/10.1073/pnas.1200081109] [PMID: 22550173]
[32]
Due H, Svendsen P, Bødker JS, et al. miR-155 as a biomarker in B-Cell malignancies. BioMed Res Int 2016; 2016: 1-14.
[http://dx.doi.org/10.1155/2016/9513037] [PMID: 27294145]
[33]
Lopez-Santillan M, Larrabeiti-Etxebarria A, Arzuaga-Mendez J, Lopez-Lopez E, Garcia-Orad A. Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: A systematic review. Oncotarget 2018; 9(32): 22850-61.
[http://dx.doi.org/10.18632/oncotarget.25230] [PMID: 29854319]
[34]
Alencar AJ, Malumbres R, Kozloski GA, et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011; 17(12): 4125-35.
[http://dx.doi.org/10.1158/1078-0432.CCR-11-0224] [PMID: 21525173]
[35]
Filip AA, Grenda A, Popek S, et al. Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL—another piece in the puzzle. Ann Hematol 2017; 96(1): 33-50.
[http://dx.doi.org/10.1007/s00277-016-2840-6] [PMID: 27730344]
[36]
Brown PJ, Ashe SL, Leich E, et al. Potentially oncogenic B-cell activation–induced smaller isoforms of FOXP1 are highly expressed in the activated B cell–like subtype of DLBCL. Blood 2008; 111(5): 2816-24.
[http://dx.doi.org/10.1182/blood-2007-09-115113] [PMID: 18077790]
[37]
Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11(3): 1065-72.
[http://dx.doi.org/10.1158/1078-0432.1065.11.3] [PMID: 15709173]
[38]
Gascoyne DM, Banham AH. The significance of FOXP1 in diffuse large B-cell lymphoma. Leuk Lymphoma 2017; 58(5): 1037-51.
[http://dx.doi.org/10.1080/10428194.2016.1228932] [PMID: 27678023]
[39]
Yu B, Zhou X, Li B, Xiao X, Yan S, Shi D. FOXP1 expression and its clinicopathologic significance in nodal and extranodal diffuse large B-cell lymphoma. Ann Hematol 2011; 90(6): 701-8.
[http://dx.doi.org/10.1007/s00277-010-1124-9] [PMID: 21120478]
[40]
Cao D, Jiang Y, Feng Y, Jing CX, Xu J, Xu CG. The value of circulating exsomal miR-451a to monitor therapy response in diffuse large B cell lymphoma. Sichuan Da Xue Xue Bao Yi Xue Ban 2018; 49(3): 399-403.
[PMID: 30014642]
[41]
Chen Z, You L, Wang L, et al. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo. J Exp Clin Cancer Res 2018; 37(1): 190.
[http://dx.doi.org/10.1186/s13046-018-0863-7] [PMID: 30103789]
[42]
Koch R, Demant M, Aung T, et al. Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma. Blood 2014; 123(14): 2189-98.
[http://dx.doi.org/10.1182/blood-2013-08-523886] [PMID: 24563408]
[43]
Koch R, Aung T, Vogel D, et al. Nuclear trapping through inhibition of exosomal export by indomethacin increases cytostatic efficacy of doxorubicin and pixantrone. Clin Cancer Res 2016; 22(2): 395-404.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0577] [PMID: 26369630]
[44]
Aung T, Chapuy B, Vogel D, et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci USA 2011; 108(37): 15336-41.
[http://dx.doi.org/10.1073/pnas.1102855108] [PMID: 21873242]